Tecnifar - Indústria Técnica Farmacêutica, S.A.
Category(ies): Pharmaceutical Companies
Address: Rua José da Costa Pedreira, 11B, Torre Sul; 1750-135 Lisboa; Portugal
Keyword(s): Advanced Therapies, Health Sciences, Molecular Mechanisms of Brain Diseases, Pharmaceuticals, Research & Development
Tecnifar, is a group of companies operating in the health sector comprising Tecnifar Pharmaceuticals, Welance and IMAG. Tecnifar pharmaceuticals is a leading company that offers innovative medicines for a wide array of conditions; Welance, a company focused on medicinal products not subject to medical prescription, medical devices and dietary supplements; and Imag, a network of diagnosis and treatment centres based on imaging techniques. A solid, all-encompassing group, now able to offer an even wider range of solutions to professionals and patients. Tecnifar's portfolio is mainly composed of prescription drugs in therapeutic areas such as CNS, Cardiology, Respiratory, Rheumatology, Diabetes and Women's health. Tecnifar commercializes its own products as well as medicines licensed in from major R&D companies, such as: Angelini, AstraZeneca, J. Uriach, Menarini, MSD and UCB. Since 2006, Tecnifar has also been undergoing R & D projects in the highly innovative and very promising area of bacteriophage therapy and has already received its first IND approval from FDA. A group that sees life where others see only health, formed by people who believe that life, having brought us this far, should inspire us to go even further. tecnifar.pt ; welance.pt; grupoimag.com
+351 000 000 000